NEW YORK and INDIANAPOLIS, May 14, 2026
Eli Lilly and Company and UNICEF USA announced a major global healthcare collaboration aimed at improving non-communicable disease (NCD) prevention and care for children and adolescents across low- and middle-income countries. Under the six-year initiative, Lilly committed $50 million to support UNICEF programs designed to strengthen healthcare systems, improve disease prevention, and expand access to early diagnosis and long-term treatment services for millions of children worldwide. The partnership is expected to reach more than 30 million children, adolescents, and caregivers across 21 countries by enhancing community-based healthcare infrastructure and pediatric disease management programs.
The initiative focuses on addressing the growing burden of childhood non-communicable diseases, including diabetes, congenital heart disease, sickle cell disease, respiratory illness, overweight, and obesity, conditions that are increasingly affecting younger populations globally. Lilly and UNICEF stated that strengthening healthcare access during early childhood is critical for reducing long-term disease burden and improving lifelong health outcomes in resource-limited settings.
Partnership Targets Rising Global NCD Burden
According to UNICEF, non-communicable diseases are rising rapidly among children and adolescents worldwide, with the greatest impact occurring in low- and middle-income countries that account for more than 82% of premature deaths linked to NCDs. Healthcare experts noted that limited access to nutritious food, preventive care, and early medical intervention continues to increase long-term health risks for vulnerable pediatric populations.
Through the collaboration, UNICEF will work alongside national governments to integrate NCD prevention and management into routine healthcare services. The initiative includes expanding access to quality care in local communities, training healthcare workers, improving disease awareness, strengthening early diagnosis programs, and enhancing long-term patient support systems for children and adolescents.
Advertisement
The organizations stated that embedding preventive healthcare programs within existing national health systems is essential for creating sustainable and scalable improvements in pediatric healthcare delivery. The program is expected to support coordinated care models capable of improving access to treatment while reducing long-term healthcare disparities in underserved regions.
Lilly Expands Global Healthcare Access Strategy
The collaboration aligns closely with Lilly’s broader 30×30 initiative, a corporate healthcare access program focused on improving access to quality healthcare for 30 million people annually in resource-limited settings by 2030. Lilly reported that it surpassed the original milestone in 2025, reaching more than 30 million individuals five years ahead of schedule.
Company executives stated that the new partnership with UNICEF extends Lilly’s commitment to global healthcare beyond medicine development by supporting healthcare infrastructure, disease prevention, and long-term patient care systems. Leadership emphasized that improving outcomes for children requires earlier intervention and stronger healthcare systems capable of identifying and managing chronic diseases before complications emerge later in life.
UNICEF officials described the collaboration as an example of how private-sector partnerships can drive large-scale public health impact through targeted investments in healthcare access and disease prevention. The organization noted that healthcare systems in many low-resource countries continue facing major challenges related to pediatric screening, chronic disease management, and continuity of care.
Global Pediatric Healthcare Innovation Gains Momentum
The six-year initiative builds upon earlier UNICEF pilot programs that evolved into sustainable multi-country healthcare models integrated into national healthcare systems. Since 2022, support from Lilly has already helped UNICEF reach nearly 16 million children and caregivers through childhood NCD awareness campaigns, health services, and healthcare system strengthening efforts.
Industry analysts continue to highlight growing pharmaceutical investment in public health partnerships, particularly in areas involving chronic disease prevention, healthcare equity, and pediatric medicine access. As non-communicable diseases increasingly impact younger populations worldwide, collaborations between pharmaceutical companies, global health organizations, and national governments are becoming central to long-term healthcare improvement strategies.
Lilly stated that the partnership reflects its broader mission of combining pharmaceutical innovation with public health initiatives to improve healthcare outcomes for underserved populations while helping strengthen healthcare systems capable of supporting future generations.
Source: Eli Lilly press release
